(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 107.76% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.95%.
Immunitybio's revenue in 2026 is $140,977,000.On average, 6 Wall Street analysts forecast IBRX's revenue for 2026 to be $237,518,934,904, with the lowest IBRX revenue forecast at $203,438,036,492, and the highest IBRX revenue forecast at $276,805,182,581. On average, 6 Wall Street analysts forecast IBRX's revenue for 2027 to be $482,903,498,175, with the lowest IBRX revenue forecast at $290,577,887,379, and the highest IBRX revenue forecast at $831,944,684,550.
In 2028, IBRX is forecast to generate $1,502,952,956,995 in revenue, with the lowest revenue forecast at $1,443,253,780,306 and the highest revenue forecast at $1,546,941,824,029.